Felipe Lott, MD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    msd
    Mitigation strategy: 
    Attest
    Date reviewed: 
    07/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    Astrazeneca
    Mitigation strategy: 
    Attest
    Date reviewed: 
    07/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    Janssen
    Mitigation strategy: 
    Attest
    Date reviewed: 
    07/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    bayer
    Mitigation strategy: 
    Attest
    Date reviewed: 
    07/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    Atsellas
    Mitigation strategy: 
    Attest
    Date reviewed: 
    07/25/2023
Return to Avanços Globais em Câncer de Bexiga (2023) - Português